Corporate Ownership Report – United Therapeutics Corp.
United Therapeutics Corporation (NASDAQ: UTHR) filed its Form 4 and related ownership disclosures on 20 July 2026, detailing a series of transactions undertaken by the reporting owner, Rothblatt Martine A.. Ms. Rothblatt serves as the company’s chairperson and chief executive officer and is also the principal insider for United Therapeutics.
Transaction Summary
| Item | Detail |
|---|---|
| Date of filings | 20 July 2026 |
| Reporting owner | Rothblatt Martine A. (chairperson, CEO) |
| Stock option exercise | 9,500 options exercised on 17 July 2026 under a 10‑b‑5‑1 trading plan adopted in late 2025 |
| Shares issued | 9,500 shares (converting the exercised options) |
| Subsequent sales | 13,200 shares sold across multiple trades on 17 July 2026 |
| Trade prices | $528.00 to $540.00 per share |
| Post‑trade holdings | 330,393 shares held directly or via a family trust |
| Other holdings disclosed | Small block held by spouse; larger block held by a trust controlled by the reporting owner’s immediate family |
| Trading plan status | Pre‑arranged plan remains in effect until the end of 2026 or upon exercise of a larger pool of options |
Analysis of Insider Activity
The exercised options and subsequent sales reflect standard execution of the pre‑arranged 10‑b‑5‑1 plan, a commonly used mechanism that allows insiders to trade in a regulated, structured manner while minimizing market impact. The sale volume of 13,200 shares, executed at a narrow price range ($528–$540), indicates a disciplined approach consistent with the plan’s parameters.
The reporting owner’s net holding of 330,393 shares post‑transactions underscores a continued substantial equity stake in the company. The presence of additional holdings—through a spouse and a family‑controlled trust—provides transparency regarding potential concentration risks and the broader distribution of ownership within the family unit.
Regulatory Context
United Therapeutics’ compliance with the Securities Exchange Act of 1934 is evident through timely disclosure of all material insider transactions. The Form 4 filings comply with the Securities and Exchange Commission’s (SEC) requirement to report trades by officers, directors, and significant shareholders within two business days of the transaction. The continued use of a pre‑arranged trading plan demonstrates adherence to the SEC’s guidance on insider trading and market manipulation, ensuring that trades are executed in a manner that mitigates adverse market effects.
Implications for Corporate Governance
The disclosure provides shareholders and analysts with a clear view of insider trading patterns and ownership structure. While the transactions are routine and fall within the parameters of the pre‑arranged plan, the high value of the trades (approximately $7 million in total sales) may be of interest to investors monitoring executive confidence in the company’s valuation. The substantial post‑trade holdings and family‑trust arrangements further emphasize the importance of transparent governance frameworks to safeguard against potential conflicts of interest.
This report synthesizes the SEC filings to present a concise yet comprehensive overview of United Therapeutics’ recent insider ownership activity, contextualized within regulatory standards and corporate governance considerations.
